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The outer membrane vesicles (OMVs) from smooth B. melitensis 16M and a derived rough mutant, VTRM1 strain, were puriﬁed
and characterized with respect to protein content and induction of immune responses in mice. Proteomic analysis showed 29
proteins present in OMVs from B. melitensis 16M; some of them are well-known Brucella immunogens such as SOD, GroES,
Omp31, Omp25, Omp19, bp26, and Omp16. OMVs from a rough VTRM1 induced signiﬁcantly higher expression of IL-12,
TNFα, and IFNγ genes in bone marrow dendritic cells than OMVs from smooth strain 16M. Relative to saline control group,
mice immunized intramuscularly with rough and smooth OMVs were protected from challenge with virulent strain B. melitensis
16M just as well as the group immunized with live strain B. melitensis Rev1 (P<0.005). Additionally, the levels of serum IgG2a
increased in mice vaccinated with OMVs from rough strain VTRM1 consistent with the induction of cell-mediated immunity.
1.Introduction
The release of outer membrane vesicles (OMVs) from bacte-
ria is a phenomenon described about 40 years ago. OMVs
are released spontaneously during the normal growth of
Gram-negative bacteria [1–3]. OMVs have been described in
both pathogenic and nonpathogenic Gram-negative bacteria
such as Escherichia coli [4, 5], Shigella spp. [6, 7], Neisseria
spp. [8], Porphyromonas spp. [9], Pseudomonas aeruginosa
[7], Helicobacter pylori [10], Vibrio spp. [11], Salmonella
spp. [12], Brucella spp. [13, 14], Actinobacillus spp. [15, 16],
Xenorhabdus nematophilus [17], and Pseudoalteromonas ant-
arctica [18].
OMVs possess a bilayer membrane and contain compo-
nentssuchaslipoproteins,outermembraneproteins(OMP),
lipopolysaccharide (LPS), and some periplasmic compo-
nents [1–3]. OMVs have been implicated in many processes
including the release of virulence factors such as proteases
and toxins, signaling between bacterial and eukaryotic cells,
DNA transfer, antibacterial activity, immunomodulation of
thehost,andfacilitationofbacterialsurvivalduringenvelope
stress [2, 3, 19, 20].
Other studies have revealed that OMVs trigger the
innate inﬂammatory response. For example, OMVs from
Salmonella typhimurium are able to activate dendritic cells to
secrete IL-12 and TNFα [12], and OMVs from Pseudomonas
aeruginosa and Helicobacter pylori are able to elicit IL-8
production by epithelial cells [21, 22].
The use of OMVs from diﬀerent Gram-negative bacteria
as acellular vaccines has been explored in recent years [23–
26]. OMV vaccines have been eﬀective in the speciﬁc case
of serogroup B of Neisseria meningitis [24]. More recently,2 Clinical and Developmental Immunology
OMVs from Vibrio cholerae and Bordetella pertusis were
demonstrated to elicit protection in mouse model [26, 27].
The interest in OMVs as vaccine carriers is increasing, and
recent reports have showed that engineered OMVs were able
to harbor overexpress antigens [28].
Brucellosis is a worldwide spread zoonotic disease trans-
mitted from domestic animals to humans. It is frequently
acquired by ingestion, inhalation, or direct contact of con-
junctiva or skin-lesions with infected animal products. The
human disease represents an important cause of morbidity
worldwide whereas animal brucellosis is associated with
serious economical losses caused mainly by abortion and
infertility in ruminants [29].
The ﬁrst eﬀective Brucella vaccine was based on live Bru-
cella abortus strain 19 (S19), a smooth strain attenuated by
an unknown process induced by its subculturing. This
strain induces reasonable protection against B. abortus in
cattle, but at the expense of persistent serological responses
that confound diﬀerential serodiagnosis of vaccinated and
ﬁeld- infected cattle. A similar problem occurs with the
B. melitensis Rev.1 strain that is still the most eﬀective
vaccine against caprine and ovine brucellosis. This problem
has been overcome in cattle by the development of the
rifampicin-resistant mutant B. abortus RB51 strain. This
strain has been proven safe and eﬀective in the ﬁeld against
bovine brucellosis and exhibits negligible interference with
diagnostic serology [30].
Currently, smooth live attenuated vaccines B. abortus S19
and B. melitensis Rev1 as well rough live attenuated vaccine
B. abortus RB51 are used in the control of animal brucellosis.
These smooth vaccines for animals may cause disease and
considered unsuitable for use in humans; the rough strain
RB51 is rifampin resistant and is considered unsuitable for
humans as rifampin is one of the antibiotics of choice for
therapy [31]. In the last few decades much research has been
done in the attempt to develop safer Brucella vaccines [32]. It
is important to mention that there is no licensed vaccine for
prevention of human brucellosis. A human vaccine could be
useful to protect farmers, veterinarians, animal care workers,
and general populations living in endemic brucellosis areas
[30].
Since OMVs from other bacteria have been used for
development of acellular vaccines, we were interested in
assessing the protective immune response induced by Bru-
cella OMVs. The ﬁrst studies related to OMVs isolated from
Brucella spp. were limited to analysis of their protein proﬁle
using one-dimensional SDS-PAGE [14, 33]. More recently,
Omp25 and Omp31 were identiﬁed in B. suis OMVs using
monoclonal antibodies [13]. In 2007, Lamontagne et al.
performedaproteomicanalysisofafractiontheycalledouter
membrane fragments from virulent B. abortus 2308 and
attenuatedBvrR/BvrSmutants[34].Todatethecomposition
of OMVs from B. melitensis has not been yet explored.
In the attempt to increase the current understanding of
the composition of B. melitensis OMVs, the proteome of
OMVs isolated from smooth B. melitensis 16M is described.
Because of the distinct immunological role of the Brucella
O-side chain in the host, mice were immunized with OMVs
puriﬁed from smooth B. melitensis 16M and the rough
mutant B. melitensis VTRM1 (lacking the side O chain of
LPS).Thediﬀerenceindendriticcellcytokineexpressionand
theserumIgGsubtypeslevelsaswellasthelevelofprotection
aﬀorded to mice is also described.
2.MaterialsandMethods
2.1. Ethics Statement. The mice experiments were approved
and conducted by Institutional Animal Care and Use Com-
mittee (approved protocol and 07-047CVM) at Virginia
Tech.
2.2. Bacterial Strains and Growth Conditions. B. melitensis
16M (ATCC 23456) and B. melitensis VTRM1 rough mutant
derived from B. melitensis 16M [35] were used. Both
strains were cultured on tryptic soy agar (TSA) plates
supplemented with 0.7% yeast extract and incubated 36h at
37◦C. Abacterialsuspensionwasobtained fromboth strains,
adjusted each to 0.5g of cells per mL of tryptic soy broth, of
which 0.5mL was spread onto each of 100 TSA plates (10cm
diameter) and incubated at 37◦Cf o r4 8h .
2.3. OMVs Puriﬁcation. The OMVs puriﬁcation was per-
formed according to the protocol described by Gamazo et
al., 1989. Brieﬂy, the bacteria were harvested with a rubber
policeman and suspended in 250mL sterile phosphate-
buﬀeredsaline(PBS0.1M,pH7.3).Thebacterialsuspension
was centrifuged at 10,000 ×g for 30min. The supernatant
was passed through a 0.22μm ﬁlter (Millipore Corp.), and
a sterility test was performed by culturing an aliquot onto a
TSAplatefollowedbyincubationfor72hat37◦C;theﬁltrate
was stored at 4◦C during the viability check. The ﬁltered
supernatant was centrifuged at 100,000 ×gf o r2 ha t4 ◦C.
The pellet was washed twice with 25mL of sterile PBS, and
the OMVs were resuspended in 1mL of sterile PBS. The total
protein concentration was determined using PIERCE-BCA
(PIERCE) reagents as per manufacturer’s recommendations.
The OMVs samples were divided into 0.5mL aliquots and
stored at −20◦C until used [33].
2.4. Bone Marrow-Derived Dendritic Cells (BMDC). Den-
dritic cells were derived from 8wk old, female BALB/c mice
by in vitro c u l t u r eo fb o n e - m a r r o wc e l l sw i t h2 0 n g / m L
rGM-CSF for 7 days as previously described [36, 37]. On
day 7, cells showed diﬀerentiated morphology (BMDC) and
expressed DC markers (CD11c+) in 75% of the population
as assessed by ﬂow cytometry (data not shown).
2.5. In Vitro Stimulation of BMDC, RNA Extraction, and
Reverse-Transcription Polymerase Chain Reaction. Aliquots
of 2.5 × 106 BMDC per well were plated in a 6-well ﬂat-
bottomed plate by triplicate and incubated overnight. Then
40μg of puriﬁed OMVs from smooth B. melitensis 16M
or OMVs from rough B. melitensis VTRM1 were added to
each well by triplicate. Total RNA (RNAeasy Qiagen) was
extracted from BMDC (stimulated and unstimulated) at 1,
3, 6, and 12h after induction. The DNA was removed with
DNase I (DNA-free Kit Ambion). Then cDNA was preparedClinical and Developmental Immunology 3
from 1μg of total RNA (Promega, A2500 kit). To verify the
complete elimination of DNA, PCR for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene ampliﬁcation was
performed (data not shown).
2.6. Real Time-PCR. Templates cDNA were analyzed for IL-
2, IL-6, IL-12p40 (IL-12), IL-10, IL-17, IL-23, INF-γ,T N F - α,
and TGF-β (SABioscienes) expression using the PCR Array
and the RT2 SYBR Green/Fluorescein qPCR Master Mix
(SABiosciences) on the iCycler PCR System (Bio-Rad) as
per recommendations of the manufacturer. Fold changes in
gene expression were calculated using the ΔΔCt method in
the PCR Array Data Analysis template. The ampliﬁcation of
house-keeping gapdh gene was used to normalize the fold
changes in the cytokine expression.
2.7. Mice Immunizations. Female BALB/c mice of 6 weeks
of age (5 per group) were vaccinated by two intramuscular
inoculations, at day 0 and day 30, with 5μgo fp u r i ﬁ e d
OMVs from B. melitensis 16M and B. melitensis VTRM1.
Before the ﬁrst dose, mice were prebled by puncturing retro-
orbital plexus under anesthesia. Two weeks after boosting,
the mice were bled by the same route. The serum was
separated from the clotted blood and stored at −20◦C until
use for detection of IgG subtypes. As a positive control, a
group of mice was vaccinated with 1.5 × 104 CFU of vaccine
strain, B. melitensis Rev1. As a negative control, one group
of mice was injected with saline. Mice were challenged at 6
weeks after the ﬁrst vaccination dose with 5 × 104 CFUs of
virulent strain B. melitensis 16M by intraperitoneal route. At
2 weeks after challenge, all the mice were euthanized by CO2
asphyxiation followed by cervical dislocation, spleens were
collected aseptically, and colony-forming units (CFU) were
determined.
2.8. Indirect ELISA. Levels of serum immunoglobulin IgG1
and IgG2a isotypes with speciﬁcity to OMVs from smooth B.
melitensis 16M and rough strain VTRM1 were determined
by indirect ELISA. Sera from mice immunized with OMVs
puriﬁed from B. melitensis 16M were tested with OMVs
puriﬁed from B. melitensis 16M, and sera from mice immu-
nized with OMVs puriﬁed from rough B. melitensis VTRM1
were tested with OMVs puriﬁed from rough strain. The
OMVs were diluted in carbonate buﬀer, pH 9.6. The wells
of polystyrene plates (Nunc-Immunoplate with maxisorp
surface) were coated with 100μL/well of the diluted antigens
(2.5μg/mL of protein from OMVs). Following overnight
incubation at 4◦C, plates were washed four times in wash
buﬀer (Tris-buﬀered saline at pH 7.4, .05% Tween 20) and
blocked with 2% bovine serum albumin (BSA) in Tris-
buﬀered saline. After 1h incubation at 37◦C, mice sera with
appropriate dilution in blocking buﬀer were added to the
wells (50μL/well). Each serum sample was tested in triplicate
wells; the plates were incubated for 4h at room temperature
and washed four times. Horse radish peroxidase-labeled
anti-mouse isotype-speciﬁc conjugates (Southern Biotech-
nology Associates Inc, Birmingham, Alabama) were added
(50μL/well) at an appropriate dilution. After 1h incubation
at room temperature, the plates were washed four times.
A 100μL of substrate solution (TMB Microwell peroxidase
substrate; Kirkegaard and Perry Laboratories, Gaithersburg,
Md) was applied to each well. After 20min incubation at
room temperature, the enzyme reaction was stopped by
adding 100μL of stop solution (0.185M sulfuric acid), and
the absorbance at 492nm was recorded using microplate
reader (Molecular Devices, Sunnyvale, Calif).
2.9. Electron Microscopy. 20μL of puriﬁed OMVs (25μgo f
protein) or intact bacteria were placed onto copper grids
coated with formvar and dried using ﬁlter paper. 40μLo f1 %
phosphotungstic acid was added, and the grids were allowed
to stand overnight at room temperature; they were observed
under the transmission electron microscope (JEOL model
JEM 10-10).
2.10. Denaturing Gel Electrophoresis. SDS-PAGE was per-
formed in 15% acrylamide slab gels by the method of
Laemmli [38]; the gels were stained with Coomassie blue.
The apparent molecular masses of the OMV proteins were
determined by comparing their electrophoretic mobility
with that of the wide-range molecular mass markers [Sigma-
Marker (Sigma)] using the computer program SigmaGel V.
1.0.
2.11. Enzymatic Digestion. After the separation of OMV
proteins by denaturing electrophoresis, the acrylamide gel
was cut into six sections. The excised samples were reduced
with 50mM dithiothreitol, alkylated with iodoacetamide
and then “in gel” digested with trypsin. The peptides were
desalted using a ZipTip (Millipore Corp) and then concen-
trated in a Speed-Vac SPD 1010 ThermoElectron (Instituto
Nacional de Biotecnologia-UNAM, Cuernavaca, M´ exico).
2.12.LC-MS/MS. Thesampleswerereconstitutedtoapprox-
imately 0.1–0.5μg/μL in 50% acetonitrile containing 1%
acetic acid and placed directly into a Finnigan LCQ ion trap
mass spectrometer (Instituto Nacional de Biotecnologia-
UNAM, Cuernavaca, Mexico), using a Surveyor MS syringe
pump delivery system. The eluate at 10μL/min was split
to allow only 5% of the sample to enter the nanospray
source (0.5μL/min). LC-MS/MS analyses were carried out
using a PicoFrit needle/column RP C18 from New Objective
(Woburn, Mass, USA), with a fast gradient system from 5%
to60%ofsolutionB(100%acetonitrilecontaining1%acetic
acid) for a period of 45min.
The electrospray ionization source voltage was set at
1.8kV and the capillary temperature at 130◦C. Collision-
Induced Dissociation (CID) was performed using 25V of
collision energy, 35–45% (arbitrary units) of normalized
collision energy and the scan had the wide band activated.
All spectra were obtained in the positive-ion mode. Data
acquisition and the deconvolution of data were carried out
using Xcalibur software on a Windows XP PC system. The
MS/MS spectra from enzymatically generated peptides were
analyzed by Sequest software from Finnigan (Palo Alto,4 Clinical and Developmental Immunology
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Figure 1: Electron microscopy of OMVs from smooth B. melitensis M16 and rough B. melitensis VTRM1. Negative stain of OMVs released
from surface B. melitensis VTRM1 (a) and B. melitensis 16M (b); negative stain of OMV puriﬁed by diﬀerential centrifugation from both
strains; B. melitensis VTRM1 (c) and B. melitensis 16M (d). The arrows point to the apparent shedding of the OMVs from the cell surface in
(a) and (b); while the arrows in (c) and (d) point to spherical OMVs puriﬁed from both strains. The bars correspond to 100nm.
Calif) and MASCOT search engine from Matrix Science Ltd
(Boston, Mass).
2.13. In Silico Analysis. Once the proteins in the OMVs
were identiﬁed, an in silico analysis was performed. Ini-
tially the amino acid sequences of the identiﬁed pro-
teins were analyzed by BLAST comparing them to sim-
ilar sequences from species of Brucella and other bacte-
ria (http://www.ncbi.nlm.nih.gov/BLAST/). The isoelectric
point and molecular weight were determined using Anthe-
prot 2000 V. 5.2.
The prediction of “motif” sequences was performed
by searching My Hits Motif Scan database (http://hits.isb-
sib.ch/cgi-bin/PFSCAN) that uses diﬀerent databases such
as PROSITE, HAMAP, and Pfam. The prediction of the
subcellular location of the proteins was carried out on the
PSORT server available at http://www.psort.org [39]a n d
Softberry database. The MatGAT V. 2.02 [40]p r o g r a mw a s
used to determinate the similitude grade of the homolo-
gous sequences found by the BLAST search. The ProLinks
database (http://dip.doe-mbi.ucla.edu/pronav/)[ 41]a n d
Gene Ontology (http://www.geneontology.org)[ 42]w e r e
used to determinate the hypothetical function of proteins
into OMVs.
2.14. Statistical Analysis. Statistical analysis, Two-Way-
ANOVA, was carried out with SigmaStat statistical package
V. 2.0 (SYSTAT).
3. Results
3.1. Isolation of OMVs and Electron Microscopy. OMVs
were isolated from cell-free culture medium by diﬀerential
centrifugation. In order to conﬁrm puriﬁcation of the OMVs
from both strains, electron micrographs were performed
using negative staining with phosphotungstic acid. In the
micrographs (Figure 1), it is possible to see the bleb for-
mation leading to the liberation of OMVs from the outer
surface of the Brucella. In addition, the spherical morphol-
ogy (average diameter 60–90nm) of the puriﬁed OMVs
including a double membrane can be observed as previously
described [14, 33]. Moreover, no membrane debris bigger
than 100nm were observed by electron microscopy. In
general, no diﬀerences, at least in the shape or in the number
of OMVs released, were observed for the smooth or rough
Brucella strains.
3.2. Cytokine Expression. In order to explore if OMVs could
induce an immune response in antigen-presenting cells, weClinical and Developmental Immunology 5
u s e dB M D Ce x p o s e dt oO M V se i t h e rf r o ms m o o t ho rr o u g h
B. melitensis. At increasing times following exposure, the
cytokinesassociatedwiththeDC1-mediatedTh1(IFN-γ,IL -
2, IL-6, IL-12, and TNF-α), DC2-mediated Th2 (IL-4 and
IL-10), and DC17-mediated Th17 (IL-17, IL-23, and TGF-β)
responsesweremeasuredbyqRT-PCR.Theresultsareshown
in Table S1 (see in table S1 Supplementary Material available
online at doi: 10.1155/2012/352493). The cytokine proﬁles
elicited in the BMDC stimulated with smooth B. melitensis
16M OMVs reached a maximum at 12 hours following
stimulation with the highest production of IL-6, IL-4, IL-
10, and IL-17 (Figure 2(a)). In contrast, the induction of
cytokines by rough OMVs reached maximum expression at
1h after stimulation and decreased over time, except for
IL-10 (maximum expression at 3 hours) and for TNF-α
(maximumexpressionat3hours)(Figure 2(b)).Usingstatis-
tical analysis we compared the cytokine expression obtained
fromBMDCstimulatedwithOMVsfromsmoothandrough
Brucella strains (Two-way-ANOVA analysis). Results showed
signiﬁcant diﬀerences between the cytokine proﬁle induced
by OMVs puriﬁed from rough and smooth B. melitensis
(P<0.05). OMVs from rough B. melitensis VTRM1
inducedthreecytokinesthatweresigniﬁcantlyhigher:IFN-γ,
TNF-α,a n dI L - 1 2( P<0.05, P<0.01 and P<0.001, resp.).
3.3. Protection against Challenge with Virulent B. melitensis
16M. Micewerechallengedwith virulentstrainB. melitensis
16M to examine the protection induced by OMVs. In this
experiment,protectionwasdeﬁnedasasigniﬁcantreduction
in the number of bacteria in the spleens of immunized mice
compared to the mice receiving saline. The B. melitensis
Rev1 vaccine induced 2.64 log units of protection compared
to saline control (Figure 3). In the case of mice vaccinated
withOMVs,weobserved thatsmooth OMVsinduced 1.9log
units, and rough OMVs induced 3.08log units of protection
compared to saline control (P<0.005).
3.4. Serology. Presence of antibodies speciﬁc to OMVs in
serum of the mice vaccinated was determined by ELISA.
The induction of IgG2a subclass during immune response
should give an idea about Th1 or Th2 balance. As illustrated
in Figures 4(a) and 4(b) OMVs puriﬁed from rough B.
melitensis VTRM1 induced a higher IgG2a response than
IgG1, suggesting a shift toward a Th1 response. In contrast,
OMVs from smooth strain B. melitensis 16M induced the
same levels of IgG1 and IgG2a.
3.5. SDS-PAGE and Proteomic Analysis. The denatured elec-
trophoretic protein proﬁles observed from OMVs obtained
from rough B. melitensis VTRM1 and smooth B. meliten-
sis 16M show no discernable diﬀerences (Figure 5). The
trypsin-generated peptide masses, as well as their fragment
ions, were analyzed by LC-MS/MS. The resulting peptides
sequences were used to query databases that led to the
identiﬁcation of 29 unique proteins (Table 1). A query result
was only considered as signiﬁcant if the overall score was
higher than 25 and more than two tryptic peptides as well as
theirfragmentionsmatchedtotheproteinandthecalculated
molecular weight corresponded to molecular weight in the
original gel section [43].
3.6.InSilicoAnalysis. Theresultsoftheproteomiccharacter-
ization of the B. melitensis vesicular proteins are summarized
in Table 1. In addition, the complete results are available in
supporting information Table S2 and Table S3. The identiﬁ-
cation score varied from 55 to 100%, with coverage from 3 to
50%. Besides the identiﬁcation of each spot and calculation
of its basic biochemical characteristics, the isoelectric point
and molecular weight was obtained by means of analysis
and search in databases. Subcellular location, protein motifs,
immunogenic regions, signal peptide prediction, and closest
homologueswerealsoanalyzed.Ofthe29proteinsidentiﬁed,
approximately 52% belonged to the outer membrane, 17%
to the periplasm, 20.6% to the cytoplasm, 2 proteins were
from inner membrane, and 1 protein was predicted to be
an extracellular protein. Using the Motif databases these
proteins were classiﬁed into ﬁve groups: (i) structural and
transport proteins (such as the outer membrane proteins),
(ii) antigenic proteins, (iii) involved in metabolic processes
(e.g., Frr, HU, GroES), (iv) involved in stress response (e.g.,
Dps, TrxC, and SOD), and v) invasion proteins (e.g., InvB
and IalB). About 60% of the proteins were predicted to
contain signal peptides and thus capable to be exported
or targeted by the cellular machinery to the periplasm or
outermembrane.Onlytwelveproteinsdidnotcontainsignal
peptides, ﬁve of these were predicted as cytoplasmic or
mature periplasmic proteins in which the signal sequence
was processed.
Additionally, the analysis of sequences using ProLinks
[41] showed that with the exception of two proteins, the
possible functions of 27 proteins were predicted. While the
analysis of sequences using Gene Ontology terms showed
that one half (14/29) of the proteins appeared to be involved
in transport and/or integrity of the membrane.
All the proteins found in the B. melitensis OMVs were
highly related to homologous proteins in other Brucella
species (from 88 to 100% in similarity, data not shown).
Formostproteins,theclosestnon-Brucellahomologueswere
found in Rhizobia,s u c ha sRhizobium and Bartonella (50%
to 90% in similarity). Interestingly, four proteins with a high
degree of homology to those in Escherichia coli were found:
FrpB (an iron-regulated outer membrane protein), a metal
chelate outer membrane receptor, Dps (involved in DNA
protection due to starvation or stationary phase), and SOD
(a Cu/Zn superoxide dismutase).
4. Discussion
As has been described in other Gram-negative bacteria,
OMVsarereleasedfromtheBrucella’s outer membrane as we
observed by electron microscopy (Figure 1). The OMVs are
shed from both rough and smooth Brucella strains, grown in
liquid or on solid media, and spontaneously released during
the growth as observed previously [13, 14, 33].
OMVs can also strongly activate the host innate and
acquired immune response pathways [23]. Based on this6 Clinical and Developmental Immunology
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Figure 2: Cytokine expression of BMDC stimulated with OMVs. (a) BMDC stimulated with OMVs from smooth B. melitensis 16M. (b)
BMDC stimulated with OMVs from rough B. melitensis VTRM1. Two-way ANOVA analysis was performed to compare results.
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Table 1: B. melitensis 16M OMVs proteins identiﬁed by 1D-SDS-PAGE coupled to LC-MS/MS.
Protein B. melitensis
denomination Molecular weight (kDa) Motif, subcellular
localization
Closest ortholog, other than
in Brucellae (% similarity)
Bacterial surface antigen BMEI0830 85.90 Surface antigen, OM
Outer membrane protein
Bartonella henselae str.
Houston-1, (75.3%)
Iron-regulated outer
membrane protein FRPB BMEII0105 72.05 TonB-dependent receptor
Plug Domain, OM
TonB-dependent receptor
Escherichia coli, (41.3%)
Metal chelate outer
membrane receptor BMEI0657 64.80 TonB-dependent receptor
Plug Domain, OM
Chain A, Outer Membrane
Cobalamin Transporter
(Btub) Escherichia coli,
(46.2%)
Sugar-binding protein BMEII0590 43.20 Bacterial sugar-binding
extracellular protein, P
Probable sugar ABC
transporter substrate binding
protein Rhizobium etli,
(75.7%)
Outer surface protein BMEII0376 31.55 Surface antigen, OM
Probable heat-resistant
agglutinin 1 protein
Rhizobium leguminosarum bv.
viciae, (54.9%)
D-Ribose-binding
periplasmic protein
precursor
BMEII0435 30.99
Periplasmic binding
protein and sugar-binding
domain of LacI family, P
Porin Rhizobium
leguminosarum bv. trifolii,
(59.2%)
Hypothetical protein
BMEI0542 BMEI0542 30.04 Unknown, EC Hypothetical protein
Rhizobium sp., (48.3%)
25kDa outer-membrane
immunogenic protein
precursor
BMEI1007 25.24 Porin type 2, OM
Hemin-binding C protein
Bartonella tricoborum,
(58.7%)
25kDa outer-membrane
immunogenic protein
precursor
BMEI1249 23.18 Porin type 2, OM
Hemin-binding B protein
Bartonella henselae str.
Houston-1, (58.7%)
25kDa outer-membrane
immunogenic protein
precursor
BMEI1829 24.58 Porin type 2, OM
Hemin-binding C protein
Bartonella tricoborum,
(45.4%)
25kDa outer-membrane
immunogenic protein
precursor
BMEI1830 24.74 Porin type 2, OM Outer membrane protein
Rhizobium etli, (60.1%)
31kDa outer-membrane
immunogenic protein
precursor
BMEII0844 23.27 OmpA-like domain
proﬁle, OM
Porin Rhizobium
leguminosarum bv. trifolii,
(52.5%)
BP26 BMEI0536 24.77 Protein of unknown
function (DUF541), P
Unknown function protein
DUF541 Rhizobium
leguminosarum bv. trifolii,
(64.9%)
Precursor YBIS protein BMEI1369 23.51 Domain YkuD, C
Hypothetical protein
Rhizobium leguminosarum bv.
viciae, (67.2%)
OmpA family protein BMEI0786 22.96 OmpA-like domain, OM
OmpA family protein
Rhizobium leguminosarum bv.
viciae, (81.4%)
Hypothetical lipoprotein BMEI0785 21.91
Prokaryotic membrane
lipoprotein lipid
attachment proﬁle, IM
Hypothetical protein
Rhizobium leguminosarum bv.
viciae, (74.7%)
Ribosome recycling
factor BMEI0826 20.66 Ribosome recycling factor
(RRF-frr), C
Ribosome recycling factor
Bartonella henselae str.
Houston-1, (90.3%)
Hypothetical
membrane-associated
protein (BMEII0692)
BMEII0692 20.42 Invasion-associated locus
B (IalB) protein, IM
Invasion-associated locus B
family protein Rhizobium
leguminosarum bv. trifolii,
(62.4%)8 Clinical and Developmental Immunology
Table 1: Continued.
Protein B. melitensis
denomination Molecular weight (kDa) Motif, subcellular
localization
Closest ortholog, other than
in Brucellae (% similarity)
22kDa outer membrane
protein precursor BMEI0717 19.44 Unknown, OM
Outer membrane protein
putative precursor Rhizobium
leguminosarum bv. viciae,
(48.6%)
DNA
starvation/stationary
phase protection protein
Dps
BMEI1980 18.25 Dps protein family
Ferritin-like domain, C
DNA starvation/stationary
phase protection protein Dps
Escherichia coli, (72.5%)
Peptidoglycan-associated
lipoprotein BMEI0340 18.23 OmpA family protein,
OM
Outer membrane lipoprotein
Rhizobium etli, (82.6%)
Invasion protein B BMEI1584 18.03 Invasion-associated locus
B (IalB) protein, P
Invasion-associated locus B
protein Bartonella quintana
str. Tolouse, (55.4%)
Outer membrane
lipoprotein BMEI0135 17.60 Bacterial outer membrane
lipoprotein; Omp19, OM
Outer membrane lipoprotein
Bartonella henselae str.
Houston-1, (59.6%)
Chain A, Cu-Zn
superoxide dismutase BMEII0581 16.07 Cu-Zn superoxide
dismutase, P
Cu-Zn superoxide dismutase
Escherichia coli, (68.7%)
Thioredoxin C-1 BMEI2022 11.42 Thioredoxin active site, C
Putative thioredoxin
Rhizobium leguminosarum bv.
viciae, (88.8%)
Cochaperonin GroES BMEII1047 10.39 10kDa chaperonin
protein Cnp10, C
Cochaperonin GroES
Bartonella tricoborum,
(91.8%)
DNA-binding protein
HU BMEI0877 9.07
Bacterial histone-like
DNA binding protein
signature, C
DNA-binding protein
Rhizobium sp., (83.5%)
Hypothetical lipoprotein Unknown 8.286
Prokaryotic membrane
lipoprotein lipid
attachment proﬁle, OM
17kDa surface antigen
Rhizobium leguminosarum bv.
trifolii, (61.2%)
Hypothetical protein
BMEI0287 BMEI0287 8.596
Prokaryotic membrane
lipoprotein lipid
attachment proﬁle, OM
Hypothetical protein
Rhizobium etli, (56.8%)
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Figure 3: Analysis of IgG1 (a) and IgG2a (b) antibody responses
of BALB/c mice to outer membrane vesicles from Brucella.O u t e r
membrane vesicles (OMVs) were puriﬁed from B. melitensis 16M
and B. melitensis VTRM1, and mice were immunized. Sera from
each mouse were collected and were assayed individually by ELISA.
Antibody levels are expressed as optical density (OD) at 492nm.
previous evidence, we stimulated BMDC with OMVs iso-
lated from smooth and rough Brucella strains. At diﬀerent
time points, cytokines expression for DC1-mediated Th1
(IFN-γ, IL-2, IL-6, IL-12, and TNF-α), DC2-mediated Th2
(IL-4 and IL-10), and DC-mediated Th17 (IL-17, IL-23
and TGF-β) was analyzed by qRT-PCR. Interestingly, we
d e t e r m i n e dt h a tO M V sf r o mr o u g hB. melitensis VTRM1
induced signiﬁcantly higher expression of IFN-γ,T N F - α,
and IL-12.
TNF-α is necessary for full expression of the macrophage
anti-Brucella activities. It also plays an important role in the
triggering of speciﬁc immunity against several intracellular
pathogens and positively controls early expression of IL-
12 and IFN-γ in Brucella-infected mice [44]. Our results
demonstrated an earlier expression of IL-12 and IFN-γ
by OMVs from rough B. melitensis VTRM1 (Figure 2(b)).
Clearly TNF-α participates in the establishment of acquired
immunity of the Th1 response, with the generation of
IFN-γ-producing CD4+ cells and CD8+ cytotoxic cells, two
outcomes crucial for the complete killing of the intracellularClinical and Developmental Immunology 9
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Figure 4: Level of protection against B. melitensis 16M conferred by outer membrane vesicles puriﬁed from B. melitensis 16M and B.
melitensis VTRM1. In this experiment vaccine strain B. melitensis Rev1 was used as a positive control of vaccination, as negative control was
used saline. n = 5(
∗P ≤ 0.005 comparisons were OMVs versus saline, and B. melitensis Rev1 versus saline).
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Figure 5: Electrophoretic proﬁles of OMVs puriﬁed from B.
melitensis. Lane 1, molecular weight markers; lane 2, OMVs from
smooth B. melitensis 16M (80μg); lane 3, OMVs from rough
B. melitensis VTRM1 (80μg). SDS-PAGE gels were stained with
Coomassie blue.
Brucella.T N F - α produced a synergistic eﬀect in presence of
IFN-γ for the ultimate clearance of the infection [45].
The early expression of IL-6, IL-23, and TGF-β genes
was observed in BMDC stimulated with OMVs from rough
B. melitensis VTRM1. In contrast, in the case of smooth B.
melitensis 16M OMVs, the same cytokines genes were ex-
pressed after a longer time with a maximum expression at
12hfollowinginduction.Theearlyinductionofthecytokine
expression could oﬀer a fast immune response against
Brucella, for example, if IL-6 promotes a proinﬂammatory
environment. However, the role of the IL-23 and TGF-β as
part of the Th17 response in Brucella infection is not very
clear to date. Some data suggest that a Th17 response is
favored when IL-6 is present in high quantities, especially in
aged mice [46].
The determination of whether Th17 response is merely
present as epiphenomena or truly playing a role in the host
defense is a focus of current research. We speculate that these
diﬀerences could be the eﬀect of the O-side chain in the LPS
present in the OMVs from the smooth strain but not in the
OMVs derived from rough B. melitensis VTRM1. In contrast
totheinfectionwithsmoothB.abortusandB.suisstrainsand
puriﬁed smooth LPS, infection of human DCs with rough
mutants of Brucella leads to both phenotypic and functional
maturation of infected cells [47].
Recently, Surendran et al. observed phenotypic matu-
ration and production of IL-12 and TNF-α when murine
BMDC were stimulated with live B. abortus RB51, a rough
vaccine strain approved by the USDA for use in cattle and
with B. abortus RB51SOD, which overexpressed a Cu-Zn
superoxidedismutase(SOD)[37].Incontrastnomaturation
or secretion of either cytokine occurred when B. abortus
strain 2308 was used to stimulate murine BMDC [47]. While
Billard et al., [47] observed higher production of TNF-α and
human DC maturation using rough mutants but not with
smooth strains of B. suis, our cytokine expression results are
in agreement with the works published by Billard et al., and
Surendran et al. Those are in conﬂict with the reports by
Zwerdling et al. and Macedo et al., where it was observed
that smooth B. abortus exposure induced human and
murine DC maturation, respectively [48]. Zwerdling et al.
could only speculate the reasons for these discrepancies
and some considerations were made such as: the diﬀerent
method for cell isolation, the concentration of the DC and
the interactions between themselves in each experiment, and
the type of strains used for those experiments [48].10 Clinical and Developmental Immunology
The direct eﬀect of puriﬁed rough or smooth LPS
molecules on human DC maturation also has been explored
[47] .H o w e v e rn od i ﬀerence could be determined between
DC responses to rough or smooth LPS of B. abortus. These
results are in line with the very low endotoxic properties
of Brucella LPS and with the equivalent stimulation of
macrophages by rough and smooth LPS [47]. This means
that the ability of rough Brucella strains to induce human
or murine DC maturation is not related to a direct eﬀect of
their LPS but maybe the absence of the O-side chain could
allow the exposure of bacterial surface molecules that should
normally be hidden. It is also possible that the absence of O-
side chain in the rough OMVs permits a higher exposure to
the outer membrane proteins. For example, it is well known
thatOmp16andOmp19interactwiththeTLR2receptorand
induce the production of IL-12, which is important for the
control of infection [44].
Recently,itwasdemonstratedthatOmp16requiresTLR4
interaction for the activation of DC and macrophages and
elicits a Th1 and protective immune response [49]. On the
other hand TLR4 is not involved in the Th1 and protective
response induced by Omp19 [32].
After intramuscular administration of OMVs from B.
melitensis 16M and rough B. melitensis VTRM1, challenge
with virulent B. melitensis 16M was performed in BALB/c
mice. Relative to saline control group, mice immunized
intramuscularly with rough OMVs were protected from
challengewithstrainvirulentB.melitensis16Mjustaswellas
the groups immunized with live strains B. melitensis Rev1 or
OMVs from rough strain B. melitensis VTRM1 (P<0.005)
(Figure 3).
In addition to protection, in this study, we analyzed
the humoral immune response induced in mice by OMVs
isolated from smooth and rough Brucella strains. Since the
subclass of IgG response is determined by the pattern of
cytokines secreted by CD4 helper T cells, we measured
the titers of both the IgG1 and IgG2a antibodies produced
against OMVs. As has been observed (Figure 4(b)), OMVs
from the rough strain were able to induce a higher IgG2a
subclass. This IgG2a isotype is important because of the
binding of their Fc portion to Fc receptors on the surface of
phagocytes that activates a broad spectrum of antimicrobial
responses (e.g., phagocytosis, cytokine synthesis, release of
inﬂammatory mediators, and generation of reactive oxidant
species) [50].
The information related to the immune response of
OMVs from Brucella is limited to observe the antigenicity
of these entities in rabbits as reported previously [33]; on
the other hand using monoclonal antibodies other authors
were able to identify two proteins in OMVs from B. suis
[13]. In the same line, there are no reports regarding the
immune protection of vaccines based on OMVs against
Brucella infection in mouse model.
Many vaccine candidates for human brucellosis involve
live attenuated Brucella strains, subunits vaccines, recombi-
nant proteins, and DNA vaccines which have shown to be
protective in a mouse model [31].
The biophysical properties of vesicles, as heterogeneous,
proteinaceous, amphipathic structures, may allow greater
movement through tissues. As a result, vesicles could travel
deeper into tissues where resident phagocytes are located
[2]. As mentioned previously, the practical application of
OMVs as acellular vaccines has been exploited in other
pathogens [24, 26, 27]. The advantage to make vaccines
based on Brucella OMVs could be that they are able to carry
many antigens exposed naturally in the outer membrane
and periplasm of Brucella; on the other hand, OMVs are
acellular entities that could give an alternative to make safer
vaccines instead of using live Brucella vaccines, which have
the additional potential complications of replication, viru-
lence, and side eﬀects due to induction of a strong immune
response (i.e., fever).
Proteomics approaches have been used to identify the
protein components of vesicles in attempts to provide
clues to the mechanisms of vesicles production and cargo
loading [51]. In this study conventional SDS-PAGE coupled
to LC-MS/MS was used to identify the composition of
B. melitensis 16M OMVs. The denatured electrophoretic
protein proﬁles observed from OMVs obtained from rough
B. melitensis VTRM1 and smooth B. melitensis 16M showed
no discernable diﬀerences (Figure 5). The method selected
forOMVspuriﬁcationwasthatonereportedforBrucellaspp
by Gamazo et al. in 1989, in which the authors observed a
range of sizes in OMVs when Brucella was grown in solid
media [33]. We also observed a slightly better yield of OMVs
when solid medium was used instead of liquid medium to
grow Brucella.
In comparing our results with Gamazo and Moriyon
[33], in 1987, they observed an electrophoretic proﬁle that
showed two major bands (25 and 30kDa) and several minor
bands (18, 22, and 84kDa) in the OMVs of both smooth
B. melitensis 16M and a rough strain B. melitensis B115.
Our results showed bands similar to those observed by
Gamazo and Moriyon, [14] in both smooth and rough
OMVs. However, the same research group in 1989 working
with OMVs puriﬁed from ﬁeld strains of B. melitensis and
B. ovis observed diﬀerent electrophoretic proﬁles divided in
four groups of proteins: A (25.5–32kDa), B (21.5–22.5kDa),
C (18–19.5kDa), and D (13–15.5kDa); these proﬁles were
diﬀerent from that reported in 1987. The diﬀerences may be
due to inherent diﬀerences between ﬁeld strains compared
with the reference strain.
After electrophoretic separation, the OMVs proteins
from B. melitensis 16M were excised and digested with
trypsin. The trypsin-generated peptide masses, as well as
their fragment ions, were analyzed by LC-MS/MS. The
resulting peptides sequences were used to query databases
led to the identiﬁcation of 29 unique proteins (Table 1). Our
results showed that the outer membrane proteins are the
principalcomponentsofBrucellaOMVsashasbeenreported
previously for other Gram-negative bacteria [23, 41, 52].
However, Lamontagne et al. (2007) found that periplasmic
and cytoplasmic proteins as the principal components of
OMVs from B. abortus while outer membrane proteins were
present as a smaller proportion.
In OMVs from B. melitensis 16M we identiﬁed Omp25
and Omp31 that belong to the major outer membrane pro-
tein family [53]. Boigegrain et al. (2004) identiﬁed Omp25Clinical and Developmental Immunology 11
and Omp31 in OMVs from B. suis using monoclonal anti-
bodies. Also, Lamontagne et al. (2007) using mass spectrom-
etry were able to identify the Omp31b and Omp25 (Omp3a)
in OMVs from B. abortus. The spontaneous release of the
OMVs and gentle isolation procedures should minimize
cytoplasmic leakage and prevent the contamination that
follows cell disruption [51]. Our analyses did not show the
presence of inner membrane markers in OMVs composition
including NADH-cytochrome C-oxidoreductase or succi-
nate dehydrogenase.
In our study, outer membrane proteins with an OmpA
motif were identiﬁed; these have been involved in immunos-
timulatory activities and induce leukocyte migration [54].
The presence of the family Ton B-dependent receptor pro-
teins could be an alternative mechanism for Brucella survival
in nutrient-limiting conditions such as found in macro-
phages [18, 55]. Additionally, Ton B-dependent receptors
have been involved in siderophore internalization [18].
Omp16, and the Omp19 are lipoproteins that induce
immunological protection very similarly to that elicited by
the live vaccine B. abortus S19 with the induction of IFN-
γ and CD4+ as well as CD8+ T-cells [29, 48, 56]. Also, the
Omp16 shows signiﬁcant similarity to the peptidoglycan-
associated lipoprotein (PALs) of many Gram-negative bac-
teria [57].
Lipoproteins Omp10, Omp16 and Omp19 were previ-
ously identiﬁed in OMVs from B. abortus by Western blot
[58].
OMVs from B. melitensis 16M contain Cu-Zn SOD, Dps,
and GroES that are part of the antioxidant defense system
thatprotectsbacteriafromthetoxiceﬀectsofreactiveoxygen
intermediates (ROIs) [59, 60]. The Dps protein has been
reported in other pathogens (Escherichia coli, Campylobacter
jejuni, and Salmonella enterica) to be responsible for resis-
tance to oxidative stress and protecting the DNA against
ROIs. The Dps protein has a ferritin-like domain (Table 1)
and is thought to nullify the toxic combination of Fe (II) and
peroxide [60, 61].
5. Conclusion
In summary, we identiﬁed 29 proteins in OMVs released by
B. melitensis 16M, some of them are well-known Brucella
immunogenssuchasSOD,GroES,Omp31,Omp25,Omp19,
bp26, and Omp16. Additionally, we determined that rough
OMVs both stimulate a stronger innate response, as well
as protective immunity against B. melitensis 16M challenge.
Based on these data, the potential of using rough OMVs of
Brucella as an acellular vaccine should be considered.
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